CVRX News and Press, CVRx Inc. From 10/26/23

CVRx Inc. (CVRX) is expected to report $-0.57 for Q3 2023

MINNEAPOLIS, Oct. 12, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with ca...

2023-09-03 08:50:29 ET Summary CVRx Inc's has recovered towards previous highs following the fallout of its BeAT-HF trial results in February 2023. Adoption and utilization of its Barostim product have continued to accelerate. The company has seen significant growth in unit vo...

MINNEAPOLIS, July 27, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that ...

2023-07-25 22:08:02 ET CVRx, Inc. (CVRX) Q2 2023 Earnings Conference Call July 25, 2023 5:30 PM ET Company Participants Mike Vallie – Senior Vice President-ICR Westwicke Nadim Yared – President and Chief Executive Officer Jared Oasheim – Chie...

2023-07-25 16:46:38 ET CVRx press release ( NASDAQ: CVRX ): Q2 GAAP EPS of -$0.56 beats by $0.02 . Revenue of $9.5M (+88.9% Y/Y) beats by $0.93M . U.S. Heart Failure ( HF ) revenue for the second quarter of 2023 was $8.3 million compared to $3.8 in the prio...

MINNEAPOLIS, July 25, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its f...

MINNEAPOLIS, July 11, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with ca...

2023-06-22 16:54:34 ET CVRx ( NASDAQ: CVRX ) will join the Russell 2000 Index and the broad-market Russell 3000 Index, the company said Thursday. The company will be added at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. marke...

MINNEAPOLIS, June 22, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that ...